ES2208167T3 - PROCEDURE FOR THE PREPARATION OF N- (5-DIFENYL-PHOSPHINOYLMETHYL) -4- (4-FLUOROPHENYL) -6-ISOPROPILPIRIMIDIN-2-IL) -N-METHYLMETHANE-SULFONAMIDE. - Google Patents

PROCEDURE FOR THE PREPARATION OF N- (5-DIFENYL-PHOSPHINOYLMETHYL) -4- (4-FLUOROPHENYL) -6-ISOPROPILPIRIMIDIN-2-IL) -N-METHYLMETHANE-SULFONAMIDE.

Info

Publication number
ES2208167T3
ES2208167T3 ES00105011T ES00105011T ES2208167T3 ES 2208167 T3 ES2208167 T3 ES 2208167T3 ES 00105011 T ES00105011 T ES 00105011T ES 00105011 T ES00105011 T ES 00105011T ES 2208167 T3 ES2208167 T3 ES 2208167T3
Authority
ES
Spain
Prior art keywords
fluorophenyl
chlorodiphenylphosphine
reaction
methyl
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00105011T
Other languages
Spanish (es)
Inventor
Walter Dr. Brieden
Ulrich Dr. Veith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lonza AG
Original Assignee
Lonza AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lonza AG filed Critical Lonza AG
Application granted granted Critical
Publication of ES2208167T3 publication Critical patent/ES2208167T3/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/78Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509Six-membered rings
    • C07F9/6512Six-membered rings having the nitrogen atoms in positions 1 and 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Procedimiento para la preparación de N-[5-(di- fenil-fosfinoilmetil)-4-(4-fluorofenil)-6-isopropilpirimidin-2-il]-N-metilmetanosulfonamida de la **fórmula** caracterizado porque se hace reaccionar [4-(4-fluorofenil)-6-isopropil-2-(N-metil-N-metilsulfonil- amino)pirimidin--5-il] metanol de la fórmula con clorodifenilfosfina.Procedure for the preparation of N- [5- (di-phenyl-phosphinoylmethyl) -4- (4-fluorophenyl) -6-isopropylpyrimidin-2-yl] -N-methylmethanesulfonamide of the ** formula ** characterized in that it is reacted [4- (4-fluorophenyl) -6-isopropyl-2- (N-methyl-N-methylsulfonyl-amino) pyrimidin-5-yl] methanol of the formula with chlorodiphenylphosphine.

Description

Procedimiento para la preparación de N-[5-(difenil-fosfinoilmetil)-4-(4-fluorofenil)-6-isopropilpirimidin-2-il]-N-metilmetano-sulfonamida.Procedure for the preparation of N- [5- (diphenyl-phosphinoylmethyl) -4- (4-fluorophenyl) -6-isopropylpyrimidin-2-yl] -N-methylmethane-sulfonamide.

La presente invención se refiere a un procedimiento para la preparación de N-[5-(difenil-fosfinoilmetil)-4-(4-fluorofenil)-6-isopropilpirimidin-2-il]-N-metilmetano-sulfonamida de la fórmulaThe present invention relates to a procedure for the preparation of N- [5- (diphenyl-phosphinoylmethyl) -4- (4-fluorophenyl) -6-isopropylpyrimidin-2-yl] -N-methylmethane-sulfonamide of the formula

1one

La N-[5-(difenilfosfinoilmetil)-4-(4-fluorofenil)-6-isopropilpirimidin-2-il]-N-metilmetanosulfonamida (I), que
puede prepararse de acuerdo con la invención, es un producto intermedio para la preparación de principios farmacéuticamente activos, por ejemplo de inhibidores de la HMG-Co A reductasa (Bioorg. Med. Che. 1997, 5, 437).
N- [5- (diphenylphosphinoylmethyl) -4- (4-fluorophenyl) -6-isopropylpyrimidin-2-yl] -N-methylmethanesulfonamide (I), which
It can be prepared according to the invention, it is an intermediate product for the preparation of pharmaceutically active ingredients, for example of HMG-Co A reductase inhibitors (Bioorg. Med. Che. 1997, 5, 437).

La misión de la invención consistía en encontrar un acceso mejorado al producto intermedio antes citado.The mission of the invention was to find improved access to the intermediate product mentioned above.

El problema podía resolverse con el nuevo procedimiento según la reivindicación 1.The problem could be solved with the new method according to claim 1.

De acuerdo con la invención la preparación de la N-[5-(difenilfosfinoilmetil)-4-(4-fluorofenil)-6-isopropilpirimidin-2-il]-N-metilmetanosulfonamida de la fórmula (I) se efectúa por reacción de [4-(4-fluorofenil)-6-isopropil-2-(N-metil-N-metilsulfonil-amino)-pirimidin-5-il]metanol de la fórmula (II)According to the invention the preparation of the N- [5- (diphenylphosphinoylmethyl) -4- (4-fluorophenyl) -6-isopropylpyrimidin-2-yl] -N-methylmethanesulfonamide of the formula (I) is carried out by reaction of [4- (4-fluorophenyl) -6-isopropyl-2- (N-methyl-N-methylsulfonyl-amino) -pyrimidin-5-yl] methanol of the formula (II)

2two

con clorodifenilfosfina.with chlorodiphenylphosphine

Una importante ventaja de la síntesis de acuerdo con la invención es su disponibilidad a gran escala.An important advantage of the agreement synthesis With the invention is its large-scale availability.

El [4-(4-fluorofenil)-6-isopropil-2-(N-metil-N-metilsulfonilamino)pirimidin-5-il]metanol de la fórmula (II) es accesible de manera fácil por reducción del correspondiente éster con, p. ej., hidruro de di-isobutilamino (documento EP-A-0521471).The [4- (4-fluorophenyl) -6-isopropyl-2- (N-methyl-N-methylsulfonylamino) pyrimidin-5-yl] methanol of the formula (II) is easily accessible by reducing the corresponding ester with, p. eg hydride of di-isobutylamino (document EP-A-0521471).

La reacción de [4-(4-fluorofenil)-6-isopropil-2-(N-metil-N-metilsulfonilamino)pirimidin-5-il]metanol de la fórmula (II) con clorodifenilfosfina puede efectuarse bien directamente o a través de una desprotonización previa. Se prefiere la reacción directa con clorodifenilfosfina, con subsiguiente tratamiento con una base.The reaction of [4- (4-fluorophenyl) -6-isopropyl-2- (N-methyl-N-methylsulfonylamino) pyrimidin-5-yl] methanol of the formula (II) with chlorodiphenylphosphine can be carried out well directly or through prior deprotonization. It preferred direct reaction with chlorodiphenylphosphine, with subsequent base treatment.

Según la variante "desprotonización" se mezcla el [4-(4-fluorofenil)-6-isopropil-2-(N-metil-N-metilsulfonil-ami- no)pirimidin-5-il]metanol de la fórmula (II) convenien-temente con un agente desprotonizador habitual en el sector técnico, ventajosamente con un hidruro de álcali o un hexaalquildisilazano alcalino. Se emplea preferentemente hidruro de sodio.According to the "deprotonization" variant mix the [4- (4-fluorophenyl) -6-isopropyl-2- (N-methyl-N-methylsulfonyl-ami- no) pyrimidin-5-yl] methanol of formula (II) conveniently with an agent Deprotonizer usual in the technical sector, advantageously with an alkali hydride or an alkaline hexaalkyldisilazane. Is used preferably sodium hydride.

Habitualmente, la desprotonización se realiza a la temperatura ambiente. Después de esto se efectúa la reacción con clorodifenilfosfina. La reacción con clorodifenilfosfina se realiza convenientemente a una temperatura entre 80ºC y 200ºC.Usually, deprotonization is performed at ambient temperature After this the reaction is carried out with chlorodiphenylphosphine The reaction with chlorodiphenylphosphine is carried out conveniently at a temperature between 80 ° C and 200 ° C.

La clorodifenilfosfina puede actuar directamente como disolvente. No obstante, es posible emplear adicionalmente un disolvente inerte de punto de ebullición lo más elevado posible, tal como p. ej. tolueno o xileno o decalina, así como las correspondientes mezclas de isómeros.Chlorodiphenylphosphine can act directly as a solvent However, it is possible to additionally use a inert boiling point solvent as high as possible, as p. ex. toluene or xylene or decalin, as well as corresponding mixtures of isomers.

La reacción puede producirse en presencia de un catalizador. Como catalizador son apropiados yodo, yoduros alcalinos tales como, p. ej., yoduro de sodio o potasio, los halogenuros de alquilo tales como, p. ej., yoduro de metilo o de etilo, o los alcanos dihalogenados tales como, p. ej., el dibromometano. Se emplea preferentemente un yoduro alcalino. La cantidad de catalizador se elige habitualmente en el intervalo de 1% en mol a 20% en moles, referido al alcohol empleado de la fórmula II.The reaction may occur in the presence of a catalyst. Iodine, iodides are suitable as catalyst alkalis such as, e.g. e.g., sodium or potassium iodide, alkyl halides such as, e.g. e.g., methyl or iodide ethyl, or dihalogenated alkanes such as, e.g. eg the dibromomethane An alkaline iodide is preferably used. The amount of catalyst is usually chosen in the range of 1% in mol to 20% in moles, based on the alcohol used by the formula II

La reacción según la variante directa transcurre convenientemente a una temperatura de -20ºC a 130ºC, preferentemente de +20ºC a 120ºC.The reaction according to the direct variant takes place conveniently at a temperature of -20ºC to 130ºC, preferably from + 20 ° C to 120 ° C.

La clorodifenilfosfina puede, según la variante "desprotonización", actuar directamente como disolvente. No obstante, es posible emplear adicionalmente un disolvente inerte de punto de ebullición lo más elevado posible, tal como p. ej. toluno o xileno o decalina, así como las correspondientes mezclas de isómeros.Chlorodiphenylphosphine can, depending on the variant "deprotonization", act directly as a solvent. Do not However, it is possible to additionally use an inert solvent of boiling point as high as possible, such as p. ex. toluno or xylene or decalin, as well as the corresponding mixtures of isomers

A continuación de la reacción con clorodifenilfosfina se combina la mezcla de reacción con una base. Son bases apropiadas los hidróxidos alcalinos o los carbonatos alcalinos tales como, p. ej., una solución acuosa de hidróxido sódico o potásico, o de carbonato sódico o potásico.Following the reaction with Chlorodiphenylphosphine combines the reaction mixture with a base. Alkaline hydroxides or carbonates are appropriate bases alkalis such as, e.g. eg, an aqueous hydroxide solution sodium or potassium, or sodium or potassium carbonate.

Eventualmente, para acelerar la reacción con la base ppuede emplearse un catalizado habitual de transferencia de fases tal como, p. ej., un halogenuro de tetraalquilamonio. Se pueden lograr también buenos resultados mediante la aplicación de éteres corona.Eventually, to speed up the reaction with the base can be used a usual transfer catalytic phases such as, e.g. eg, a tetraalkylammonium halide. I know they can also achieve good results by applying crown ethers

La N-[5-(difenilfosfinoilmetil)-4-(4-fluorofenil)-6-isopropilpirimidin-2-il]-N-metilmetanosulfonamida de la fórmula I puede aislarse, una vez terminada la reacción, de manera conocida por el personal técnico, p. ej. mediante extracción con un disolvente apropiado de la mezcla de reacción, así como por cristalización en la mezcla.The N- [5- (diphenylphosphinoylmethyl) -4- (4-fluorophenyl) -6-isopropylpyrimidin-2-yl] -N-methylmethanesulfonamide of the formula I can be isolated, once the reaction is over, from way known to technical staff, p. ex. by extraction with an appropriate solvent of the reaction mixture, as well as by crystallization in the mixture.

Ejemplos Examples Ejemplo 1Example 1 N-[5-(difenilfosfinoilmetil)-4-(4-fluorofenil)-6-iso-propilpirimidin-2-il]-N-metilmetanosulfonamida N- [5- (diphenylphosphinoylmethyl) -4- (4-fluorophenyl) -6-iso-propylpyrimidin-2-yl] -N-methylmethanesulfonamide

Se dispusieron en 5 ml de cis/trans-decalina 1,00 g (2,83 milimoles) de [4-(4-fluorofenil)-6-isopropil-2-(N-metil-N-metilsulfonil-amino)-pirimidin-5-il]metanol y se mezclaron con 204 mg (4,68 milimoles) de hidruro sódico (dispersión al 55% en aceite mineral). Después de 30 min a la temperatura ambiente se añadieron bajo agitación vigorosa durante 6 min 680 mg (2,93 milimoles) de clorodifenilfosfi-na. Se mezcló con 52,2 mg (0,35 milimoles) de yoduro sódico y se calentó durante 2 h 15 min hasta 184-186ºC. Después de enfriar hasta la temperatura ambiente se mezcló con 50 ml de solución de hidrógeno-sulfito sódico al 38-40% y 50 ml de acetato de etilo. Se separó la fase orgánica y la fase acuosa se extrajo con 50 ml de acetato de etilo. Las fases orgánicas reunidas se secaron sobre sulfato magnésico y se concentró al vacío. Se obtuvieron 1,74 g de producto bruto que se purificaron mediante cromatografía a través de gel de sílice (eluyente: n-hexano/acetato de etilo 1:2). Se obtuvieron 382,4 mg (25,1%) de N-[5-(difenilfosfino-ilmetil)-4-(4-fluorofenil)-6-isopropilpirimidin-2-il]-N-me-tilmetanosulfonamida en forma de un sólido incoloro. (Punto de fusión 184 - 185ºC).They were placed in 5 ml of cis / trans-decalin 1.00 g (2.83 mmol) of [4- (4-fluorophenyl) -6-isopropyl-2- (N-methyl-N-methylsulfonyl-amino) -pyrimidin-5-yl] methanol and mixed with 204 mg (4.68 mmol) of sodium hydride (55% dispersion in mineral oil). After 30 min at room temperature was added under vigorous stirring for 6 min 680 mg (2.93 mmol) of chlorodiphenylphosphine It was mixed with 52.2 mg (0.35 millimoles) of sodium iodide and heated for 2 h 15 min until 184-186 ° C. After cooling to temperature ambient was mixed with 50 ml of solution 38-40% sodium hydrogen sulphite and 50 ml of ethyl acetate. The organic phase and the phase were separated Aqueous was extracted with 50 ml of ethyl acetate. Phases The combined organics were dried over magnesium sulfate and concentrated under vacuum 1.74 g of crude product were obtained and purified. by chromatography through silica gel (eluent: n-hexane / ethyl acetate 1: 2). 382.4 were obtained mg (25.1%) of N- [5- (diphenylphosphino-ylmethyl) -4- (4-fluorophenyl) -6-isopropylpyrimidin-2-yl] -N-me-tilmethanesulfonamide in the form of a colorless solid. (Melting point 184-185 ° C).

       \newpage\ newpage
    

^{1}H RMN (DMSO-d^{6}, 400 MHz): \delta =1 H NMR (DMSO-d 6, 400 MHz): δ = 1,11 (d, J = 6,6 Hz, 6J);1.11 (d, J = 6.6 Hz, 6J); 3,28 (sept, J = 6,6 Hz, 1H);3.28 (Sept, J = 6.6 Hz, 1 HOUR); 3,40 (s, 3H);3.40 (s, 3H); 3,51 (s, 3H);3.51 (s, 3H); 4,05 (d, J = 12,6 Hz, 2H);4.05 (d, J = 12.6 Hz, 2H); 7,07 (t, J = 8,9 Hz, 2H);7.07 (t, J = 8.9 Hz, 2H); 7,35 (m, 2H);7.35 (m, 2H); 7,42 (m, 4H);7.42 (m, 4H); 7,5 - 7,9 (m, 6H).7.5 - 7.9 (m, 6H). ^{13}C RMN (DMSO-d^{6}, 100 MHz): \delta =13 C NMR (DMSO-d 6, 100 MHz): δ = 21,52 (q);21.52 (q); 29,12 (td);29.12 (td); 31,94 (d);31.94 (d); 33,07 (q);33.07 (q); 41,53 (q);41.53 (q); 114,50 (sd);114.50 (sd); 115,03 (dd);115.03 (dd); 128,54 (dd);128.54 (dd); 130,21 (dd);130.21 (dd); 130,84 (dd);130.84 (dd); 131,64 (dd);131.64 (dd); 133,41 (sd);133.41 (sd); 134,51 (sd);134.51 (sd); 156,54 (sd);156.54 (sd); 162,10 (sd);162.10 (sd); 165,86 (sd);165.86 (sd); 176,49 (sd).176.49 (sd).

Ejemplo 2Example 2 N-[5-(difenilfosfinoilmetil)-4-(4-fluorofenil)-6-iso-propilpirimidin-2-il]-N-metilmetanosulfonamida N- [5- (diphenylphosphinoylmethyl) -4- (4-fluorophenyl) -6-iso-propylpyrimidin-2-yl] -N-methylmethanesulfonamide

Se dispusieron en 4,5 ml de xileno (mezcla de isómeros) 282,8 mg (0,80 milimoles) de [4-(4-fluorofenil)-6-isopropil-2-(N-metil-N-metilsulfonilamino)pirimidin-5-il]metanol y se mezclaron con 55 mg (1,30 milimoles) de hidruro sódico (dispersión al 55% en aceite mineral). Después de 35 min se añadieron a temperatura ambiente, bajo agitación vigorosa, durante 5 min 185 mg (0,84 milimoles) de clorodifenilfosfina en 1,5 ml de xileno y, a continuación, se calentó durante 20 h hasta 135ºC. Después de enfriar hasta la temperatura ambiente, se mezcló con 15 ml de agua y se extrajo con 10 ml de acetato de etilo. La fase orgánica se separó y la fase acuosa se extrajo con 2 x 10 ml de acetato de etilo. A continuación se secaron las fases orgánicas reunidas (MgSO_{4}) y se concentró al vacío. Se obtuvieron 510 mg de producto bruto, que se purificó por cromatografía sobre gel de sílice (eluyente: n-hexano/acetato de etilo 1 : 2, luego acetato de etilo) y se aislaron 230 mg (53,5%) de N-[5-(difenil-fosfinoilmetil)-4-(4-fluorofenil)-6-isopropilpirimidin-2- il]-N-metilmetanosulfonamida en forma de un sólido incoloro.They were placed in 4.5 ml of xylene (mixture of isomers) 282.8 mg (0.80 mmol) of [4- (4-fluorophenyl) -6-isopropyl-2- (N-methyl-N-methylsulfonylamino) pyrimidin-5-yl] methanol and mixed with 55 mg (1.30 mmol) of sodium hydride (55% dispersion in mineral oil). After 35 min it added at room temperature, under vigorous stirring, for 5  min 185 mg (0.84 mmol) of chlorodiphenylphosphine in 1.5 ml of xylene and then heated for 20 h at 135 ° C. After cooling to room temperature, it was mixed with 15 ml of water and extracted with 10 ml of ethyl acetate. The phase The organic was separated and the aqueous phase was extracted with 2 x 10 ml of ethyl acetate. The organic phases were dried pooled (MgSO4) and concentrated in vacuo. 510 mg were obtained of crude product, which was purified by gel chromatography of silica (eluent: n-hexane / ethyl acetate 1: 2, then ethyl acetate) and 230 mg (53.5%) of N- [5- (diphenyl-phosphinoylmethyl) -4- (4-fluorophenyl) -6-isopropylpyrimidin-2- il] -N-methylmethanesulfonamide in form of a colorless solid.

Ejemplo 3Example 3 N-[5-(difenilfosfinoilmetil)-4-(4-fluorofenil)-6-iso-propilpirimidin-2-il]-N-metilmetanosulfonamida N- [5- (diphenylphosphinoylmethyl) -4- (4-fluorophenyl) -6-iso-propylpyrimidin-2-yl] -N-methylmethanesulfonamide

Se dispusieron previamente en 8 ml de tolueno 512 mg (1,45 milimoles) de [4-(4-fluorofenil)-6-isopropil-2-(N-metil-N-metilsulfonilamino)pirimidin-5-il]metanol y se mezclaron con 96 mg (2,20 milimoles) de hidruro sódico (dispersión al 55% en aceite mineral). Después de 1 h se añadieron a la temperatura ambiente bajo agitación vigorosa durante 5 min 333,5 mg (1,44 milimoles) de clorodifenilfos-fina en 2,5 ml de tolueno. Se mezcló con 28,7 mg (0,19 milimoles) de yoduro sódico y se calentó durante 22 h hasta 108ºC. Después de 6 h se mezcló con otros 28,7 mg (0,19 milimoles) de yoduro sódico. Después de enfriar hasta la temperatura ambiente se mezcló con 30 ml de solución de hidrógeno-sulfito sódico al 38-40% y se extrajo con 50 ml de acetato de etilo. La fase orgánica se separó y la fase acuosa se extrajo con 50 ml de acetato de etilo. A continuación se concentraron al vacío las fases orgánicas reunidas. Se obtuvieron 740 mg de producto bruto, que mediante cromatografía sobre gel de sílice (eluyente: acetato de etilo) se purificaron y se aislaron 212,7 mg (27,3%) de N-[5-(difenilfosfinoilmetil)-4-(4-fluorofenil)-6-isopropilpirimidin-2-il]-N-metilmetanosulfonamida en forma de un sólido incoloro.They were previously placed in 8 ml of toluene 512 mg (1.45 millimoles) of [4- (4-fluorophenyl) -6-isopropyl-2- (N-methyl-N-methylsulfonylamino) pyrimidin-5-yl] methanol and mixed with 96 mg (2.20 mmol) of sodium hydride (55% dispersion in mineral oil). After 1 h they were added to ambient temperature under vigorous stirring for 5 min 333.5 mg (1.44 mmol) of chlorodiphenylphosphine in 2.5 ml of toluene It was mixed with 28.7 mg (0.19 mmol) of iodide sodium and heated for 22 h to 108 ° C. After 6 h it mixed with another 28.7 mg (0.19 millimoles) of sodium iodide. After cooling to room temperature was mixed with 30 ml of sodium hydrogen sulphite solution at 38-40% and extracted with 50 ml of ethyl acetate. The organic phase was separated and the aqueous phase was extracted with 50 ml of ethyl acetate. The phases were then concentrated in vacuo Organic gathered. 740 mg of crude product were obtained, which by chromatography on silica gel (eluent: acetate ethyl) were purified and 212.7 mg (27.3%) of N- [5- (diphenylphosphinoylmethyl) -4- (4-fluorophenyl) -6-isopropylpyrimidin-2-yl] -N-methylmethanesulfonamide in the form of a colorless solid.

Ejemplo 4Example 4 N-[5-(difenilfosfinoilmetil)-4-(4-fluorofenil)-6-iso-propilpirimidin-2-il]-N-metilmetanosulfonamida N- [5- (diphenylphosphinoylmethyl) -4- (4-fluorophenyl) -6-iso-propylpyrimidin-2-yl] -N-methylmethanesulfonamide

Se dispusieron en 8 ml de xileno (mezcla de isómeros) 502,6 mg (1,42 milimoles) de [4-(4-fluorofenil)-6-isopropil-2-(N-metil-N-metilsulfonilamino)pirimidin-5-il]metanol y se mezclaron con 96,6 mg (2,21 milimoles) de hidruro sódico (dispersión al 55% en aceite mineral). Después de 1 h se añadieron a la temperatura ambiente, bajo agitación vigorosa y durante 5 min, 340,8 mg (1,47 milimoles) de clorodifenil-fosfina en 2,5 ml de xileno. Se mezclaron con 34,6 mg (0,23 milimoles) de yoduro sódico y se calentó durante 19 h hasta 136ºC. Después de 3 h se mezclaron con otros 25,1 mg de yoduro sódico. Después de enfriar hasta la temperatura ambiente se mezcló con 30 ml de solución diluida de hidrógeno-sulfito sódico y se extrajo con 50 ml de acetato de etilo. La fase orgánica se separó y la fase acuosa se extrajo con 50 ml de acetato de etilo. A continuación se concentraron al vacío las fases orgánicas reunidas. Se obtuvieron 906 mg de producto bruto, que se purificó por cromatografía sobre gel de sílice (eluyente: acetato de etilo), y se aislaron 315,9 mg (41,3%) de N-[5-(difenil-fosfinoilmetil)-4-(4-fluorofenil)-6-isopropilpirimidin-2-il]-N-metilmetanosulfonamida en forma de un sólido incoloro.They were placed in 8 ml of xylene (mixture of isomers) 502.6 mg (1.42 mmol) of [4- (4-fluorophenyl) -6-isopropyl-2- (N-methyl-N-methylsulfonylamino) pyrimidin-5-yl] methanol and mixed with 96.6 mg (2.21 mmol) of sodium hydride (55% dispersion in mineral oil). After 1 h they were added to room temperature, under vigorous stirring and for 5 min, 340.8 mg (1.47 mmol) of chlorodiphenyl phosphine in 2.5 ml of xylene. They were mixed with 34.6 mg (0.23 mmol) of sodium iodide and heated for 19 h to 136 ° C. After 3 h mixed with another 25.1 mg of sodium iodide. After cooling until room temperature was mixed with 30 ml of solution diluted sodium hydrogen sulphite and extracted with 50 ml of ethyl acetate. The organic phase was separated and the phase Aqueous was extracted with 50 ml of ethyl acetate. Then you concentrated the combined organic phases in vacuo. They were obtained 906 mg of crude product, which was purified by chromatography on silica gel (eluent: ethyl acetate), and 315.9 mg were isolated (41.3%) of N- [5- (diphenyl-phosphinoylmethyl) -4- (4-fluorophenyl) -6-isopropylpyrimidin-2-yl] -N-methylmethanesulfonamide in the form of a colorless solid.

Ejemplo 5 (reacción directa)Example 5 (reaction direct)

N-[5-(difenilfosfinoilmetil)-4-(4-fluorofenil)-6-iso-propilpirimidin-2-il]-N-metilmetanosulfonamida N- [5- (diphenylphosphinoylmethyl) -4- (4-fluorophenyl) -6-iso-propylpyrimidin-2-yl] -N-methylmethanesulfonamide

Se dispusieron en 7 g de tolueno bajo enfriamiento con baño de hielo 1,05 g (2,95 milimoles) de [4-(4-fluorofenil)-6-isopropil-2-(N-metil-N-metilsulfonil-amino)pirimidin-5-il]metanol y se mezclaron bajo agitación con 820 mg (3,69 milimoles) de clorodifenilfosfina. Se calentó durante 3 h hasta 108ºC. Después de enfriar hasta la temperatura ambiente, se mezcló con 553 mg (4,43 milimoles) de lejía acuosa de potasa (al 45%) y 97,5 mg (0,29 milimoles) de bromuro de tetrabutilamonio y se agitó fuertemente durante 1 h a 60ºC. La fuente de calor se retiró y la mezcla de reacción, todavía caliente, se mezcló con 20 ml de agua. Se dejó enfriar lentamente hasta 4ºC y se separó por filtración el sólido precipitado. El producto se lavó con agua fría y tolueno y se secó al vacío a 40ºC. Se aislaron 1,04 g (64,1%; contenido: 97,6%) de N-[5- (difenilfosfinoil-metil)-4-(4-fluorofenil)-6-isopropilpirimidin-2-il]-N-metil-metanosulfonamida en forma de un sólido incoloro.They were placed in 7 g of low toluene 1.05 g (2.95 mmol) ice bath cooling [4- (4-fluorophenyl) -6-isopropyl-2- (N-methyl-N-methylsulfonyl-amino) pyrimidin-5-yl] methanol and mixed under stirring with 820 mg (3.69 mmol) of chlorodiphenylphosphine It was heated for 3 h at 108 ° C. After cool to room temperature, mixed with 553 mg (4.43 millimoles) of aqueous lye from potash (45%) and 97.5 mg (0.29 millimoles) of tetrabutylammonium bromide and stirred strongly for 1 h at 60 ° C. The heat source was removed and the mixture of reaction, still hot, was mixed with 20 ml of water. Left cool slowly to 4 ° C and the solid was filtered off precipitate. The product was washed with cold water and toluene and was dried under vacuum at 40 ° C. 1.04 g (64.1%; content: 97.6%) of N- [5- (diphenylphosphinoyl-methyl) -4- (4-fluorophenyl) -6-isopropylpyrimidin-2-yl] -N-methyl-methanesulfonamide in the form of a colorless solid.

Ejemplo 6 (reacción directa)Example 6 (reaction direct)

N-[5-(difenilfosfinoilmetil)-4-(4-fluorofenil)-6-iso-propilpirimidin-2-il]-N-metilmetanosulfonamida N- [5- (diphenylphosphinoylmethyl) -4- (4-fluorophenyl) -6-iso-propylpyrimidin-2-yl] -N-methylmethanesulfonamide

Se dispusieron en 13 g de tolueno 2,03 g (5,69 milimoles) de [4-(4-fluorofenil)-6-isopropil-2-(N-metil-N-metilsulfonil-amino)pirimidin-5-il]metanol y bajo enfriamiento con baño de hielo se mezclaron con 1,67 g (7,51 milimoles) de clorodifenilfosfina en 2 g de tolueno. Se calentó durante 2,5 h hasta 111ºC. Después de enfriar hasta la temperatura ambiente se mezcló con 1,08 g (8,66 milimoles) de una lejía de potasa al 45% y 175 mg (0,574 milimoles) de cloruro de tetrabutilamonio y se agitó fuertemente durante 2 h a 60ºC. A la mezcla de reacción caliente se añadieron 30 ml de agua. Se agitó brevemente a 60ºC, se enfrió lentamente hasta 4ºC y se separó por filtración el sólido precipitado. El producto se lavó con agua fría (10 ml) y tolueno frío (10 ml) y se secó al vacío a 40ºC. Se aislaron 2,66 g (84,1%; contenido: 96,6%) de N-[5-(difenilfosfinoilmetil)-4-(4-fluorofenil)-6-isopropilpirimidin-2-il]-N-metilmetanosulfonamida en forma de un sólido incoloro.2.03 g (5.69 were placed in 13 g of toluene) millimoles) of [4- (4-fluorophenyl) -6-isopropyl-2- (N-methyl-N-methylsulfonyl-amino) pyrimidin-5-yl] methanol and under ice bath cooling they were mixed with 1.67 g (7.51 mmol) of chlorodiphenylphosphine in 2 g of toluene. I know heated for 2.5 h to 111 ° C. After cooling to room temperature was mixed with 1.08 g (8.66 mmol) of a 45% potash bleach and 175 mg (0.574 mmol) of tetrabutylammonium and stirred strongly for 2 h at 60 ° C. To Hot reaction mixture was added 30 ml of water. It stirred briefly at 60 ° C, slowly cooled to 4 ° C and separated by filtration the precipitated solid. The product was washed with cold water (10 ml) and cold toluene (10 ml) and dried under vacuum at 40 ° C. I know isolated 2.66 g (84.1%; content: 96.6%) of N- [5- (diphenylphosphinoylmethyl) -4- (4-fluorophenyl) -6-isopropylpyrimidin-2-yl] -N-methylmethanesulfonamide in the form of a colorless solid.

Ejemplo 7 (reacción directa)Example 7 (reaction direct)

N-[5-(difenilfosfinoilmetil)-4-(4-fluorofenil)-6-iso-propilpirimidin-2-il]-N-metilmetanosulfonamida N- [5- (diphenylphosphinoylmethyl) -4- (4-fluorophenyl) -6-iso-propylpyrimidin-2-yl] -N-methylmethanesulfonamide

Se dispusieron en 13,1 g de tolueno 2,02 g (5,69 milimoles) de [4-(4-fluorofenil)-6-isopropil-2-(N-metil-N-metilsulfonil-amino)-pirimidin-5-il]metanol y bajo enfriamiento con baño de hielo se mezclaron con 1,67 g (7,51 milimoles) de clorodifenilfosfina en 1,9 g de tolueno. Se calentó durante 3 h hasta 109ºC. Después de enfriar hasta la temperatura ambiente, se mezcló con 590 mg (8,94 milimoles) de hidróxido potásico sólido y 159 mg (0,582 milimoles) de 18-corona-6 y se agitó fuertemente durante 3,5 h a 60ºC. A la mezcla de reacción caliente se añadieron 30 ml de agua. Se agitó brevemente a 60ºC, se enfrió lentamente hasta 4ºC y se separó por filtración el sólido precipitado. El producto se lavó con agua fría (10 ml) y con tolueno frío (10 ml) y se secó al vacío a 40ºC. Se aislaron 1,82 g (59,5%; contenido: 95,9%) de [N-[5-(difenilfosfinoilmetil)-4-(4-fluorofenil)-6-isopropilpirimidin-2-il]-N-metilmetanosulfonamida en forma de un sólido incoloro.2.02 g (5.69 were placed in 13.1 g of toluene) millimoles) of [4- (4-fluorophenyl) -6-isopropyl-2- (N-methyl-N-methylsulfonyl-amino) -pyrimidin-5-yl] methanol and under ice bath cooling they were mixed with 1.67 g (7.51 millimoles) of chlorodiphenylphosphine in 1.9 g of toluene. It got hot for 3 h at 109 ° C. After cooling to temperature ambient, mixed with 590 mg (8.94 mmol) of hydroxide solid potassium and 159 mg (0.582 mmol) of 18-crown-6 and stirred heavily for 3.5 h at 60 ° C. To the hot reaction mixture were added 30 ml of water It was stirred briefly at 60 ° C, cooled slowly to 4 ° C and the precipitated solid was filtered off. The product was washed with cold water (10 ml) and with cold toluene (10 ml) and dried under vacuum at 40 ° C. 1.82 g (59.5%; content: 95.9%) of [N- [5- (diphenylphosphinoylmethyl) -4- (4-fluorophenyl) -6-isopropylpyrimidin-2-yl] -N-methylmethanesulfonamide in the form of a colorless solid.

Ejemplo 8 (reacción directa)Example 8 (reaction direct)

N-[5-(difenilfosfinoilmetil)-4-(4-fluorofenil)-6-iso-propilpirimidin-2-il]-N-metilmetanosulfonamida N- [5- (diphenylphosphinoylmethyl) -4- (4-fluorophenyl) -6-iso-propylpyrimidin-2-yl] -N-methylmethanesulfonamide

Se dispusieron en 13,1 g de tolueno 2,05 g (5,69 milimoles) de [4-(4-fluorofenil)-6-isopropil-2-(N-metil-N-metilsulfonil-amino)-pirimidin-5-il]metanol, y bajo enfria- miento con baño de hielo se mezclaron con 1,71 g (7,69 milimoles) de clorodifenilfosfina en 1,9 g de tolueno. Se calentó durante 2,5 h hasta 111ºC. Después de enfriar hasta la temperatura ambiente se mezcló con 1,17 g (8,78 milimoles) de lejía de sosa al 30% y 182 mg (0,597 milimoles) de cloruro de tetrabutilamonio y se agitó fuertemente durante 3,5 h a 60ºC. A la mezcla de reacción caliente se agregaron 30 ml de agua. Se agitó brevemente a 60ºC, se enfrió lentamente hasta 4ºC y se separó por filtración el sólido precipitado. El producto se lavó con agua fría (10 ml) y tolueno frío (10 ml) y se secó al vacío a 40ºC. Se aislaron 2,18 g (71,3%; contenido: 97,3%) de [N-[5-(difenilfosfinoilmetil)-4-(4-fluorofenil)-6-isopropil-pirimidin-2-il]-N-metilmetanosulfonamida en forma de un sólido incoloro (Punto de fusión 184-185ºC).2.05 g (5.69 were placed in 13.1 g of toluene) millimoles) of [4- (4-fluorophenyl) -6-isopropyl-2- (N-methyl-N-methylsulfonyl-amino) -pyrimidin-5-yl] methanol, and under ice bath cooling they were mixed with 1.71 g (7.69 mmol) of chlorodiphenylphosphine in 1.9 g of toluene. I know heated for 2.5 h to 111 ° C. After cooling to room temperature was mixed with 1.17 g (8.78 mmol) of bleach 30% soda and 182 mg (0.597 mmol) of chloride tetrabutylammonium and stirred vigorously for 3.5 h at 60 ° C. To Hot reaction mixture was added 30 ml of water. It stirred briefly at 60 ° C, slowly cooled to 4 ° C and separated by filtration the precipitated solid. The product was washed with cold water (10 ml) and cold toluene (10 ml) and dried under vacuum at 40 ° C. I know isolated 2.18 g (71.3%; content: 97.3%) of [N- [5- (diphenylphosphinoylmethyl) -4- (4-fluorophenyl) -6-isopropyl-pyrimidin-2-yl] -N-methylmethanesulfonamide in the form of a colorless solid (Melting Point 184-185 ° C).

Ejemplo 9 (reacción directa)Example 9 (reaction direct)

N-[5-(difenilfosfinoilmetil)-4-(4-fluorofenil)-6-iso-propilpirimidin-2-il]-N-metilmetanosulfonamida N- [5- (diphenylphosphinoylmethyl) -4- (4-fluorophenyl) -6-iso-propylpyrimidin-2-yl] -N-methylmethanesulfonamide

Una suspensión de 9,29 g (26,3 milimoles) de de [4-(4-fluorofenil)-6-isopropil-2-(N-metil-N-metilsulfonil-amino) pirimidin-5-il]metanol en 26 g de tolueno se mezcló bajo enfriamiento con baño de hielo con 7,64 g (34,4 milimoles) de clorodifenilfosfina. Se lavó con un poco de tolueno y se calentó durante 2 h hasta 111ºC. Después de enfriar hasta la temperatura ambiente se mezcló con 4,94 g de una lejía de potasa al 45% y 873 mg (2,71 milimoles) de bromuro de tetrabutilamonio y se agitó fuertemente durante 1 h a 60ºC. A la mezcla de reacción caliente se añadieron 100 ml de agua. Se agitó brevemente a 60ºC, se dejó enfriar lentamente hasta 4ºC y se separó por filtración el sólido precipitado. El producto se lavó con agua fría (30 ml) y tolueno frío (30 ml) y se secó al vacío a 40ºC. Se aislaron 11,74 g (78,4%; contenido: 94,4%) de N-[5-(difenilfosfinoilmetil)-4-(4-fluorofenil)-6-isopropilpirimidin-2-il]-N-metilmetanosulfonamida en forma de un sólido incolor.A suspension of 9.29 g (26.3 mmol) of of [4- (4-fluorophenyl) -6-isopropyl-2- (N-methyl-N-methylsulfonyl-amino)  pyrimidin-5-yl] methanol in 26 g of toluene was mixed under ice bath cooling with 7.64 g (34.4 mmol) of chlorodiphenylphosphine. He washed with a little toluene and heated for 2 h to 111 ° C. After cooling until room temperature was mixed with 4.94 g of a bleach of 45% potash and 873 mg (2.71 mmol) of bromide tetrabutylammonium and stirred strongly for 1 h at 60 ° C. To Hot reaction mixture was added 100 ml of water. It stirred briefly at 60 ° C, allowed to cool slowly to 4 ° C and separated by filtration the precipitated solid. The product was washed with water cold (30 ml) and cold toluene (30 ml) and dried under vacuum at 40 ° C. I know isolated 11.74 g (78.4%; content: 94.4%) of N- [5- (diphenylphosphinoylmethyl) -4- (4-fluorophenyl) -6-isopropylpyrimidin-2-yl] -N-methylmethanesulfonamide in the form of a colorless solid.

Ejemplo 10 (reacción directa sin catalizador de transferencia de fases)Example 10 (direct reaction without catalyst transfer of phases)

N-[5-(difenilfosfinoilmetil)-4-(4-fluorofenil)-6-iso-propilpirimidin-2-il]-N-metilmetanosulfonamida N- [5- (diphenylphosphinoylmethyl) -4- (4-fluorophenyl) -6-iso-propylpyrimidin-2-yl] -N-methylmethanesulfonamide

Se dispusieron en 13 g de tolueno 2,03 g (5,69 milimoles) de [4-(4-fluorofenil)-6-isopropil-2-(N-metil-N-metilsulfonil-amino)-pirimidin-5-il]metanol, y bajo enfriamiento con baño de hielo se mezclaron con 1,69 g (7,60 milimoles) de clorodifenilfosfina en 1,9 g de tolueno. Se calentó durante 2,5 h hasta 109ºC. Después de enfriar hasta la temperatura ambiente se mezcló con 1,09 g (8,74 milimoles) de lejía de potasa al 45% y se agitó fuertemente durante 2 h 45 minutos a 60ºC. A la mezcla de reacción caliente se añadieron 30 ml de agua. Se agitó brevemente a 60ºC, se enfrió lentamente hasta 4ºC y se separó por filtración el sólido precipitado. El producto se lavó con agua fría (10 ml) y tolueno frío (10 ml) y se secó al vacío a 40ºC. Se aislaron 2,44 g (76,8%; contenido: 99,1%) de [N-[5-(difenilfosfinoilmetil)-4-(4-fluorofenil)-6-isopropilpirimidin-2-il]-N-metilmetanosulfonamida en forma de un sólido incoloro.2.03 g (5.69 were placed in 13 g of toluene) millimoles) of [4- (4-fluorophenyl) -6-isopropyl-2- (N-methyl-N-methylsulfonyl-amino) -pyrimidin-5-yl] methanol, and under ice bath cooling they were mixed with 1.69 g (7.60 millimoles) of chlorodiphenylphosphine in 1.9 g of toluene. It got hot for 2.5 h at 109 ° C. After cooling to temperature ambient was mixed with 1.09 g (8.74 mmol) of potash bleach at 45% and stirred vigorously for 2 h 45 minutes at 60 ° C. To Hot reaction mixture was added 30 ml of water. It stirred briefly at 60 ° C, slowly cooled to 4 ° C and separated by filtration the precipitated solid. The product was washed with cold water (10 ml) and cold toluene (10 ml) and dried under vacuum at 40 ° C. I know isolated 2.44 g (76.8%; content: 99.1%) of [N- [5- (diphenylphosphinoylmethyl) -4- (4-fluorophenyl) -6-isopropylpyrimidin-2-yl] -N-methylmethanesulfonamide in the form of a colorless solid.

Ejemplo 11 (reacción directa)Example 11 (reaction direct)

N-[5-(difenilfosfinoilmetil)-4-(4-fluorofenil)-6-iso-propilpirimidin-2-il]-N-metilmetanosulfonamida N- [5- (diphenylphosphinoylmethyl) -4- (4-fluorophenyl) -6-iso-propylpyrimidin-2-yl] -N-methylmethanesulfonamide

Una solución de 60,08 g (0,170 moles) de [4-(4-fluorofenil)-6-isopropil-2-(N-metil-N-metilsulfonil-amino) pirimidin-5-il]metanol en aproximadamente 485 ml de tolueno se mezcló a 60ºC con 42,55 g (0,192 moles; contenido: 99,7%) de clorodifenilfosfina. Se agitó durante 2,5 horas y se agregó esta solución a una mezcla, caliente a 60ºC, a base de 70,66 g de lejía de potasa (al 20%) y 5,04 g (0,017 moles) de cloruro de tetrabutilamonio, y se lavó a continuación con 13 ml de tolueno. Se agitó durante 2 h a 60ºC y se añadieron 215 ml de agua y 108 ml de tolueno. Aproximadamente a 80ºC se separó la fase acuosa y se extrajo la fase orgánica todavía dos veces con 215 ml de agua caliente cada vez. Se deshidrató por vía azeotropa en el separador de agua y se dejó enfriar durante 2 h hasta 0ºC. Los cristales precipitados se separaron por filtración y se lavaron 2 veces con 160 ml de tolueno. Después de secar al vacío a 40ºC se obtuvieron 81,94 g (89,7%) de N-[5-(difenil-fosfinoilmetil)-4-(4-fluorofenil)-6-isopropilpirimidin-2-il]-N-metilmetanosulfonamida en forma de un sólido incoloro [contenido (según HPLC): 100%].A solution of 60.08 g (0.173 mol) of [4- (4-fluorophenyl) -6-isopropyl-2- (N-methyl-N-methylsulfonyl-amino) pyrimidin-5-yl] methanol in approximately 485 ml of toluene was mixed at 60 ° C with 42.55 g (0.192 moles; content: 99.7%) of chlorodiphenylphosphine. It stirred for 2.5 hours and this solution was added to a mixture, hot at 60 ° C, based on 70.66 g of potash bleach (20%) and 5.04 g (0.017 mol) of tetrabutylammonium chloride, and washed at then with 13 ml of toluene. It was stirred for 2 h at 60 ° C and was they added 215 ml of water and 108 ml of toluene. About 80 ° C the aqueous phase was separated and the organic phase was still extracted twice with 215 ml of hot water each time. He became dehydrated by azeotroped in the water separator and allowed to cool for 2 h up to 0 ° C. The precipitated crystals were filtered off and they were washed twice with 160 ml of toluene. After drying under vacuum at 40 ° C 81.94 g (89.7%) of N- [5- (diphenyl-phosphinoylmethyl) -4- (4-fluorophenyl) -6-isopropylpyrimidin-2-yl] -N-methylmethanesulfonamide in the form of a colorless solid [content (according to HPLC): 100%].

Claims (10)

1. Procedimiento para la preparación de N-[5-(difenil-fosfinoilmetil)-4-(4-fluorofenil)-6-isopropilpirimidin-2-il]-N-metilmetanosulfonamida de la fórmula1. Procedure for the preparation of N- [5- (diphenyl-phosphinoylmethyl) -4- (4-fluorophenyl) -6-isopropylpyrimidin-2-yl] -N-methylmethanesulfonamide of the formula 33 caracterizado porque se hace reaccionar [4-(4-fluorofenil)-6-isopropil-2-(N-metil-N-metilsulfonil-amino)pirimidin-5-il]metanol de la fórmula characterized in that [4- (4-fluorophenyl) -6-isopropyl-2- (N-methyl-N-methylsulfonyl-amino) pyrimidin-5-yl] methanol of the formula is reacted 44 con clorodifenilfosfina.with chlorodiphenylphosphine 2. Procedimiento según la reivindicación 1, caracterizado porque el [4-(4-fluorofenil)-6-isopropil-2-(N-metil-N-metilsulfonil-amino)pirimidin-5-il]metanol de la fórmula II se hace reaccionar directamente con clorodifenilfosfina y a continuación con una base.2. Method according to claim 1, characterized in that the [4- (4-fluorophenyl) -6-isopropyl-2- (N-methyl-N-methylsulfonyl-amino) pyrimidin-5-yl] methanol of formula II is made react directly with chlorodiphenylphosphine and then with a base. 3. Procedimiento según la reivindicación 1, caracterizado porque el [4-(4-fluorofenil)-6-isopropil-2-(N-metil-N-metilsulfonil-amino)pirimidin-5-il]metanol de la fórmula II primero se desprotoniza.3. Method according to claim 1, characterized in that the [4- (4-fluorophenyl) -6-isopropyl-2- (N-methyl-N-methylsulfonyl-amino) pyrimidin-5-yl] methanol of formula II is first Deprotonize. 4. Procedimiento según la reivindicación 3, caracterizado porque la desprotonización se efectúa con un hidruro alcalino o un hexaalquildisilazano alcalino.4. Method according to claim 3, characterized in that the deprotonization is carried out with an alkali metal hydride or an alkaline hexaalkyldisilazane. 5. Procedimiento según la reivindicación 3 ó 4, caracterizado porque la reacción se efectúa con ayuda de un catalizador.5. Method according to claim 3 or 4, characterized in that the reaction is carried out with the aid of a catalyst. 6. Procedimiento según la reivindicación 5, caracterizado porque como catalizador se emplea yodo, un yoduro alcalino, un halogenuro de alquilo o un alcano dihalogenado.Method according to claim 5, characterized in that iodine, an alkaline iodide, an alkyl halide or a dihalogenated alkane are used as catalyst. 7. Procedimiento según una de las reivindicaciones 3 a 6, caracterizado porque la reacción con la clorodifenilfosfina se efectúa a una temperatura comprendida entre 80ºC y 200ºC.Method according to one of claims 3 to 6, characterized in that the reaction with chlorodiphenylphosphine is carried out at a temperature between 80 ° C and 200 ° C. 8. Procedimiento según la reivindicación 2, caracterizado porque la reacción directa con clorodifenilfosfina se efectúa a una temperatura comprendida entre -20ºC y 130ºC.Method according to claim 2, characterized in that the direct reaction with chlorodiphenylphosphine is carried out at a temperature between -20 ° C and 130 ° C. 9. Procedimiento según la reivindicación 2 u 8, caracterizado porque como base se emplea un hidróxido alcalino.9. Method according to claim 2 or 8, characterized in that an alkali hydroxide is used as the base. 10. Procedimiento según la reivindicación 2, 8 ó 9, caracterizado porque la reacción se efectúa con ayuda de un catalizador de transferencia de fases.Method according to claim 2, 8 or 9, characterized in that the reaction is carried out with the aid of a phase transfer catalyst.
ES00105011T 1999-03-10 2000-03-09 PROCEDURE FOR THE PREPARATION OF N- (5-DIFENYL-PHOSPHINOYLMETHYL) -4- (4-FLUOROPHENYL) -6-ISOPROPILPIRIMIDIN-2-IL) -N-METHYLMETHANE-SULFONAMIDE. Expired - Lifetime ES2208167T3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP99104786 1999-03-10
EP99104786 1999-03-10
EP99104785 1999-03-10
EP99104785 1999-03-10

Publications (1)

Publication Number Publication Date
ES2208167T3 true ES2208167T3 (en) 2004-06-16

Family

ID=26152921

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00105011T Expired - Lifetime ES2208167T3 (en) 1999-03-10 2000-03-09 PROCEDURE FOR THE PREPARATION OF N- (5-DIFENYL-PHOSPHINOYLMETHYL) -4- (4-FLUOROPHENYL) -6-ISOPROPILPIRIMIDIN-2-IL) -N-METHYLMETHANE-SULFONAMIDE.

Country Status (16)

Country Link
EP (1) EP1035127B1 (en)
JP (1) JP4438167B2 (en)
KR (1) KR100586664B1 (en)
CN (1) CN1126755C (en)
AT (1) ATE251633T1 (en)
CA (1) CA2300243C (en)
CZ (1) CZ298235B6 (en)
DE (1) DE50003959D1 (en)
DK (1) DK1035127T3 (en)
ES (1) ES2208167T3 (en)
HK (1) HK1029996A1 (en)
HU (1) HU224967B1 (en)
NO (1) NO324982B1 (en)
PL (1) PL195166B1 (en)
PT (1) PT1035127E (en)
SK (1) SK284027B6 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0311195A (en) * 2002-05-21 2005-02-22 Ranbaxy Lab Ltd Rosuvastatin Preparation Process
US7341743B2 (en) 2004-10-28 2008-03-11 Revlon Consumer Products Corporation Color cosmetic compositions
WO2009143776A1 (en) 2008-05-27 2009-12-03 常州制药厂有限公司 Preparation method of rosuvastatin calcium and its intermediates

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (en) * 1991-07-01 1997-09-03 塩野義製薬株式会社 Pyrimidine derivatives

Also Published As

Publication number Publication date
CZ2000837A3 (en) 2000-10-11
CZ298235B6 (en) 2007-08-01
HUP0001127A3 (en) 2003-07-28
NO20001228D0 (en) 2000-03-09
JP4438167B2 (en) 2010-03-24
CA2300243A1 (en) 2000-09-10
PT1035127E (en) 2004-02-27
KR100586664B1 (en) 2006-06-07
NO20001228L (en) 2000-09-11
CA2300243C (en) 2009-12-29
HK1029996A1 (en) 2001-04-20
KR20010006773A (en) 2001-01-26
JP2000309595A (en) 2000-11-07
CN1126755C (en) 2003-11-05
DE50003959D1 (en) 2003-11-13
HU0001127D0 (en) 2000-05-28
SK284027B6 (en) 2004-08-03
EP1035127B1 (en) 2003-10-08
HUP0001127A2 (en) 2001-06-28
HU224967B1 (en) 2006-04-28
EP1035127A1 (en) 2000-09-13
NO324982B1 (en) 2008-01-14
PL338944A1 (en) 2000-09-11
PL195166B1 (en) 2007-08-31
SK3322000A3 (en) 2000-10-09
ATE251633T1 (en) 2003-10-15
DK1035127T3 (en) 2003-11-03
CN1272499A (en) 2000-11-08

Similar Documents

Publication Publication Date Title
ES2316349T3 (en) PROCEDURE FOR THE PRODUCTION OF (E) - (6- (2- (4- (4-FLUOROPHENYL) -6-ISOPROPIL-2- (METHYL (METILSULFONYL) AMINO) PIRIMIDIN -5-IL) VINYL) (4R, 6S) -2,2-DIMETHYL (1,3) DIOXAN-4-IL) TERC-BUTILO ACETATE.
AU2014373961B2 (en) 5-fluoro-4-imino-3-(alkyl/substituted alkyl)-1-(arylsulfonyl)-3,4-dihydropyrimidin-2(1H)-one and processes for their preparation
ES2612033T3 (en) Bosentan preparation procedure
ES2376375T3 (en) PROCEDURE FOR PREPARATION OF BOSENT�? N.
WO2016082605A1 (en) Method for preparing palbociclib
TW533204B (en) A process for preparing substituted quinazoline derivatives
ES2255973T3 (en) PREPARATION OF SULFONAMIDS.
ES2208167T3 (en) PROCEDURE FOR THE PREPARATION OF N- (5-DIFENYL-PHOSPHINOYLMETHYL) -4- (4-FLUOROPHENYL) -6-ISOPROPILPIRIMIDIN-2-IL) -N-METHYLMETHANE-SULFONAMIDE.
CN103930400B (en) Prepare method and the intermediate of 1-acyl-4-phenyl alkylsulfonyl Prolinamide derivatives
BR112020020549A2 (en) NEW PROCESS FOR THE SYNTHESIS OF A DIAMINOPYRIMIDINE PHENOXY COMPOUND
ES2251392T3 (en) PROCEDURE TO PREPARE 2-AMINO-4- (4-FLUOROPHENYL) -6-ALKYL PYRIMIDINE-5-CARBOXYLATES.
ES2302694T3 (en) PROCEDURE FOR THE PREPARATION OF (1R, 2S, 4R) - (-) - 2- (2'-N, N-DIMETHYLAMIN-ETOXI) -2-PHENYL-1,7,7-TRI-METHYL-BIKE 2.2.1 HEPTANO AND ITS PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS.
KR20200024252A (en) Substituted Quinolinylcyclohexylpropanamide Compounds and Improved Methods of Making the Same
KR101803499B1 (en) Novel process for preparing thienopyrimidine compound and intermediates used therein
TWI383974B (en) Method for preparing (3s,4s)-4-((r)-2-(benzyloxy)tridecyl)-3-hexyl-2-oxetanone and novel intermediate used therefor
US20170022169A1 (en) Intermediate compound for preparing rosuvastatin calcium and method for preparing rosuvastatin calcium therefrom
JPH06100540A (en) 5-isoquinolinesulfonic acid amide derivative
JP2007517797A (en) Preparation of highly chemical R-5- (2- (2-ethoxyphenoxyethylamino) propyl) -2-methoxybenzenesulfonamide hydrochloride
ES2364350T3 (en) PROCEDURE FOR THE PREPARATION OF 1-METHYLINDAZOL-3-CARBOXYL ACID.
US6160115A (en) Process for preparing N-[5-(diphenylphosphinoylmethyl)-4-(4-fluorophenyl)-6-isopropylpyrimidin -2-yl]-N-methylmethanesulfonamide
EP1002798A1 (en) An improved process for preparing a therapeutically active pyrazolopyrimidinone derivative
CN107434807A (en) A kind of preparation method of the azaindole of 5 hydroxyl 7
ES2204950T3 (en) INTERMEDIATE PRODUCT TO PREPARE A PHARMACEUTICALLY ACTIVE COMPOUND.
CN106749266B (en) The high efficiency preparation method of pyrrolo- [2,3-d] pyrimidines
WO2012022217A1 (en) N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)phenyl]benzamide derivatives, a preparation method and use for synthesis of imatinib thereof